BioStorage Technologies Adding New Service in Germany
News Oct 17, 2012
The expansion of vapor phase liquid nitrogen storage allows BioStorage Technologies to offer the widest range of storage options available in the industry. The company's temperature-controlled storage options include: bulk sample storage at 15 degrees Celsius to 27 degrees Celsius, cold sample storage at -20 degrees Celsius and 5 degrees Celsius, and ultra-low temperature storage at -70 degrees Celsius and -80 degrees Celsius, and liquid nitrogen storage -190 degrees Celsius. To ensure biomaterial assets are stored at the precise temperature, samples are continuously monitored and tracked by BioStorage's proprietary ISISS® technology, thereby providing a regulatory audit trail of location and movement of each sample within our facility.
"To meet the needs of our expanding client base and the growing need for biopreservation of cellular-based samples, we expanded vapor-phase liquid nitrogen storage capability in our Germany based operations, which provides our European clients with the full range of storage conditions they require for specimen preservation, ranging from -190 degrees Celsius to controlled room temperature storage," said Russ Hager, Senior Director of Global Biorepository Operations, BioStorage Technologies. "Integrating this expanded liquid nitrogen storage capability into our current processes gives our customers greater flexibility in meeting their long-term storage needs without sacrificing the level of quality and sample management they require."
BioStorage Technologies manages the complete life cycle of a sample from planning, collection, transportation, protection and retrieval to sample disposal. The company serves pharmaceutical and biotech firms, donor organizations and tissue banks, as well as research and academic organizations around the world. BioStorage Technologies maintains US FDA 21 CFR Part 11 compliant validated technology and tracking systems and adheres to global regulatory agency guidelines and regulations, as well as International Air Transport Association logistics certification and guidelines and US Department of Transportation guidelines.
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
Pathway in Neurons may Contribute to Neurodegenerative DiseaseNews
Pathway has received attention as potential drug target.READ MORE
Evotec Achieves First Milestone in Neurodegeneration Alliance with CelgeneNews
Successful completion of iPSC screening campaign.READ MORE